Control of lipid disorders in patients with atherosclerotic vascular disease

Surgical Clinics of North America

Volumn 78, Issue 3, 1998, Pages 431-446

  Marks, A D ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LORECOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINAMIDE; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; UNCLASSIFIED DRUG;

AMBLYOPIA; ATHEROGENESIS; ATHEROSCLEROSIS; DRUG MECHANISM; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPIDOSIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK FACTOR; VASCULAR DISEASE;

EID: 0031745873     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70324-8     Document Type: Article

References (48)

1. P. Amarenco O. Heinzlef Lucas C. French Study of Aortic Plaques in Stroke Group Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke N Engl J Med 334 1996 1216
2. K.M. Anderson W.P. Castelli D. Levy 30 years of follow-up from the Framingham study JAMA 257 1987 2176
3. G. Assmann H. Schulte Triglycerides and atherosclerosis: Results from the Prospective Cardiovascular Munster Study Gotto A.M. Jr Paoletti R. Atherosclerosis Reviews Vol 22 1991 Raven Press New York 51
4. Bakker-Arkema RG, Egros F, Bracs P, et al: A comparison of the efficacy of the HMG CoA reductase inhibitors [abstract]. European Atherosclerosis Society 66th Congress, Florence, 1996, pp 205
5. B.G. Brown X.Q. Zhao D.E. Sacca Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease Circulation 87 1993 1781
6. G. Brown J. Albers L. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289
7. L. Carlson A. Hamsten A. Asplund Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid J Intern Med 226 1989 271
8. W.P. Castelli R.J. Garrison P.W.F. Wilson Incidence of coronary heart disease and lipoprotein levels: The Framingham study JAMA 256 1986 2835
9. G.R. Castro C.J. Fielding Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein Biochemistry 27 1988 25
10. Conner P.L. the Coronary Drug Project Research Group Mortality in coronary drug project patients during a 9-year posttreatment period Am J Coll Cardiol 8 1986 1245
11. M.H. Criqui Triglycerides and coronary heart disease Gotto A.M. Jr Paoletti R. Atherosclerosis Reviews Vol 22 1991 Raven Press New York 75
12. M.H. Criqui R.D. Langer A. Fronek Mortality over a period of 10 years in patients with peripheral vascular disease N Engl J Med 326 1992 381
13. M.A. Denke Cholesterol lowering diet. A review of the evidence Arch Intern Med 155 1995 393
14. M.H. Frick M.O. Elo K. Haapa Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237
15. J.W. Gofman W. Young R. Tandy Ischemic heart disease, atherosclerosis, and longevity Circulation 34 1966 679
16. T. Gordon W.P. Castelli M.C. Hjortland High density lipoprotein as a protective factor against coronary heart disease: The Framingham study Am J Med 62 1977 707
17. T. Gordon W.B. Kannel W.P. Castelli Lipoproteins, cardiovascular disease, and death: The Framingham study Arch Intern Med 141 1981 1128
18. D.J. Gordon J.L. Probstfeld R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies Circulation 79 1989 8
19. J.M. Haeg Combination drug therapy Rifkind B.M. Drug Treatment of Hyperlipidemia 1991 Marcel Dekker New York 215
20. A. Hamsten G. Walldius G. Dahlen Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction Atherosclerosis 59 1986 223
21. A. Hamsten G. Walldius A. Szamosi Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction Circulation 73 1986 1097
22. Y. Henkin D.W. Garber L.C. Osterlund Saturated fats, cholesterol, and dietary compliance Arch Intern Med 152 1992 1167
23. S.B. Hulley R.H. Rosenman R.D. Bawol Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease N Engl J Med 302 1980 1383
24. International Committee for the Evaluation of Hypertriglyceridemia as a Vascular Risk Factor The hypertriglyceridemias: Risk and management Am J Cardiol 68 1991 1A
25. A. Keys C. Aravanis H. Blackburn Seven countries: A multivariate analysis of death and coronary artery disease 1980 Harvard University Press Cambridge, MA 381
26. T. Koga Y. Shimada M. Kurola Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Biochim Biophys Acta 1045 1990 115
27. P.M. Kris-Etherton D. Krummel M.E. Russell The effect of diet on plasma lipids, lipoproteins, and coronary heart disease J Am Diet Assoc 88 1988 1373
28. D. Kritchevsky S.A. Tepper J.A. Storey Influence of procetofen in lipid metabolism in normocholesterolemic rats Pharmacol Res Commun 11 1979 635
29. M.H. Luria Effect of low-dose nicotinic acid on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio Arch Intern Med 148 1988 2493
30. M. Manttari P. Koskinen V. Manninem The effect of gemfibrozil on the concentration and composition of serum lipoproteins—a controlled study with special reference to initial triglyceride levels Atherosclerosis 81 1990 11
31. G.J. Miller N.E. Miller Plasma high-density-lipoprotein concentration and development of ischaemic heart disease Lancet 1 1975 16
32. R.B. Moore C.A. Crane Frantz I.D. Jr Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesteolemic patient J Clin Invest 47 1968 1664
33. Mullin G.E. Greenson J.K. Jr M.C. Mitchell Fulminant hepatic failure after ingestion of sustained-release nicotinic acid Ann Intern Med 111 1989 253
34. National Cholesterol Education Program Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) Circulation 89 1994 1333
35. J.M. Nawrocki The treatment of primary hypercholesterolemia with atorvastatin Arterioscler Thromb Vasc Biol 15 1995 678
36. S.J. Pocock A.G. Shaper A.N. Phillips Concentrations of high-density lipoprotein cholesterol, triglycerides, and total cholesterol in ischemic heart disease Br Med J 298 1989 998
37. Pooling Project Research Group Relationship of blood pressure, serum cholesterol, relative weight and ECG abnormalities to incidence of major coronary events: Final report of the Pooling Project Am Heart Assoc Monogr 1978 60
38. Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383
39. F.M. Sacks M.A. Pfeffer L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N Engl J Med 335 1996 1001
40. J.T. Salonen R. Salonen Ultrasonographically-assessed carotid morphology and the risk of coronary heart disease Arterioscler Thromb 11 1991 1245
41. J. Shephard S.M. Cobbe I. Ford Prevention of coronary heart diseases with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301
42. J. Stamler D. Wentworth J.D. Neaton Is the relationship between serum cholesterol and risk from premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256 1986 2823
43. The Lipid Research Clinic Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary artery disease JAMA 251 1989 351
44. P.A. Todd A. Ward Gemfibrozil—a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemic patients Drugs 36 1988 314
45. G.A. Vega R.M. Krauss S.M. Grundy Pravastatin therapy in primary moderate hypercholesterolemia: Changes in metabolism of apolipoprotein B–containing lipoproteins J Intern Med 227 1990 81
46. WHO Cooperative Trial in Primary Prevention of Ischemic Heart Disease with Clofibrate to Lower Serum Cholesterol Final mortality follow-up Lancet 2 1984 600
47. O. Wiklund L. Wilhelmsen Elmfeldt Alpha-lipoprotein cholesterol concentration in relation to subsequent myocardial infarction in hypercholesterolemic men Atherosclerosis 37 1980 47
48. P.W.F. Wilson R.D. Abbott W.P. Castelli High density lipoprotein cholesterol and mortality: The Framingham Heart Study Arteriosclerosis 8 1988 737